Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2: The EMBRACE study

Trial Profile

Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2: The EMBRACE study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Olaparib (Primary)
  • Indications Breast cancer; Ovarian cancer
  • Focus Therapeutic Use
  • Acronyms EMBRACE study
  • Most Recent Events

    • 15 Nov 2017 Planned initiation date changed from 30 Sep 2017 to 30 Nov 2017.
    • 15 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 13 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top